Home Gastrointestinal Disorders Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis

Chronic_Ulcerative_Colitis_1 — Inflammatory pseudopolyps from a total colectomy done for clinically severe, intractable chronic ulcerative colitis (UC). Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program toward the end of the second quarter in about 1,400 patients with moderate-to-severe UC. [Ed Uthman, MD via Wikidata]

Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis

French biopharma gears up for Phase III trial of lead candidate ABX464 as BMS, Pfizer and Lilly pursue UC treatments

By Alex Philippidis

January 31, 2022

Inflammatory pseudopolyps from a total colectomy done for clinically severe, intractable chronic ulcerative colitis (UC). Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program toward the end of the second quarter in about 1,400 patients with moderate-to-severe UC. [Ed Uthman, MD via Wikidata]

Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program this year in about 1,400 patients with moderate-to-severe ulcerative colitis (UC). The company has held an end-of-Phase II meeting with the FDA and received scientific feedback from the European Medicines Agency. Both agencies supported ABX464 advancing into Phase III. Abivax’s treatments are designed to modulate the body’s inflammation and immunological pathways . . .